Because sites of seizure origin may be unknown or multifocal, identifying targets from which activation can suppress seizures originating in diverse networks is essential. We evaluated the ability of optogenetic activation of the deep/intermediate layers of the superior colliculus (DLSC) to fill this role. Optogenetic activation of DLSC suppressed behavioral and electrographic seizures in the pentylenetetrazole (forebrain+brainstem seizures) and Area Tempestas (forebrain/complex partial seizures) models; this effect was specific to activation of DLSC, and not neighboring structures. DLSC activation likewise attenuated seizures evoked by gamma butyrolactone (thalamocortical/absence seizures), or acoustic stimulation of genetically epilepsy prone rates (brainstem seizures). Anticonvulsant effects were seen with stimulation frequencies as low as 5 Hz. Unlike previous applications of optogenetics for the control of seizures, activation of DLSC exerted broad-spectrum anticonvulsant actions, attenuating seizures originating in diverse and distal brain networks. These data indicate that DLSC is a promising target for optogenetic control of epilepsy.
Introduction
Epilepsy affects an estimated 50 million people world-wide (Ngugi et al., 2010) . Unfortunately, up to a third of patients do not achieve seizure control with currently available pharmacotherapy (Kwan and Brodie, 2000) . Deep brain stimulation (DBS) may be beneficial in patients for whom no other therapeutic option exists, and moreover, may represent an alternative to removal of brain tissue. Current DBS targets in epilepsy (e.g., the anterior nucleus of the thalamus) show partial efficacy, but are also associated with cognitive side effects (Hartikainen et al., 2014) . Thus, identification of new targets and approaches for brain stimulation in epilepsy is particularly compelling.
One approach of interest is optogenetics; this method allows for high spatiotemporal, cell-type, and pathway specific targeting of neuronal stimulation (Boyden et al., 2005; Gradinaru et al., 2010) . Optogenetics may offer significant advantages over electrical DBS methods by minimizing issues associated with activation of fibers of passage, current spread, and cell targeting. Moreover, high-fidelity temporal control over neural firing may allow for finer tuning of patterns of activation. To date, most efforts employing optogenetics for seizure control have been primarily focused on circuitry within which the seizures are generated (Krook-Magnuson et al., 2013) , but see: (KrookMagnuson et al., 2014) . While these studies demonstrate that optogenetics can be employed to control focal seizures, clinically, the site of seizure initiation is often unknown or multifocal, as seizures may arise from interconnected but discrete brain networks (Forcelli and Gale, 2014) . Thus, evaluating endogenous circuits that can impede pathological network synchronization and exert a broad-spectrum effect is vital.
One region that has received particular attention for broad-spectrum anticonvulsant effects is the deep/intermediate layers of the superior colliculus (DLSC). Pharmacological activation of DLSC neurons or pharmacological silencing activity of the substantia nigra pars reticulata, the major inhibitory input to the DLSC, is potently anticonvulsant (Dean and Gale, 1989; Depaulis et al., 1994; Gale et al., 1993; Iadarola and Gale, 1982) . It has also been suggested that the DLSC is the critical mediator of nigral seizure control (Garant and Gale, 1987) . While the effect of DLSC activation has been well studied in seizure control using focal microinjections, this is not a translational approach. Several major drawbacks to this approach that are avoided by optogenetics are the need for chronic intracerebral drug delivery, issues associated with drug spread, and the lack of temporal control of activity. Because optogenetics allows for high-fidelity control of the timing and frequency of stimulation, this method enables examination of different stimulation paradigms, as well as stimulation both prior to and after the onset of seizure activity. 
